Docetaxel and Lycopene in Metastatic Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

July 12, 2017

Conditions
Adenocarcinoma of the Prostate
Interventions
DRUG

Lycopene and Docetaxel

During administration of standard of care Docetaxel at 75 mg/m2 on day 15 and every 21 days, study patients will also receive Lycopene at the dose specified per the dose cohort they are enrolled. There are three dose cohort levels as follows: Dose level 1 = 30 mg PO every day; Dose level 2 = 90 mg PO every day; Dose level 3 = 150 mg PO every day.Treatment will continue until disease progression or toxicity or patient withdrawal.

Trial Locations (2)

29425

Medical University of South Carolina, Charleston

Ralph H. Johnson Veterans Administration Medical Center, Charleston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Medical University of South Carolina

OTHER

NCT01949519 - Docetaxel and Lycopene in Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter